These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12143920)

  • 1. The pharmacologic treatment of depression: is gender a critical factor?
    Yonkers KA; Brawman-Mintzer O
    J Clin Psychiatry; 2002 Jul; 63(7):610-5. PubMed ID: 12143920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressants and drug-metabolizing enzymes--expert group report.
    Meyer UA; Amrein R; Balant LP; Bertilsson L; Eichelbaum M; Guentert TW; Henauer S; Jackson P; Laux G; Mikkelsen H; Peck C; Pollock BG; Priest R; Sjöqvist F; Delini-Stula A
    Acta Psychiatr Scand; 1996 Feb; 93(2):71-9. PubMed ID: 8686486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in depression and antidepressant pharmacokinetics and adverse events.
    Frackiewicz EJ; Sramek JJ; Cutler NR
    Ann Pharmacother; 2000 Jan; 34(1):80-8. PubMed ID: 10669189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic insights into depression and antidepressant response: does sex matter?
    Pitychoutis PM; Zisaki A; Dalla C; Papadopoulou-Daifoti Z
    Curr Pharm Des; 2010; 16(20):2214-23. PubMed ID: 20459391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
    Kirchheiner J; Bertilsson L; Bruus H; Wolff A; Roots I; Bauer M
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S235-43. PubMed ID: 14677085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.
    Jann MW; Cohen LJ
    Drug Metabol Drug Interact; 2000; 16(1):39-67. PubMed ID: 10820582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of antidepressant drugs.
    Horstmann S; Binder EB
    Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review.
    Bigos KL; Pollock BG; Stankevich BA; Bies RR
    Gend Med; 2009 Dec; 6(4):522-43. PubMed ID: 20114004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and interactions of antidepressants in the treatment of co-morbid illness.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2009 Sep; 21(3):399-400. PubMed ID: 19794364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism.
    Porcelli S; Fabbri C; Spina E; Serretti A; De Ronchi D
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1101-15. PubMed ID: 21736534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant pharmacodynamics, pharmacokinetics, and drug interactions.
    Ereshefsky L
    Geriatrics; 1998 Dec; 53 Suppl 4():S22-33. PubMed ID: 9861902
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics.
    Cohen LJ; De Vane CL
    Ann Pharmacother; 1996 Dec; 30(12):1471-80. PubMed ID: 8968460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing pharmacologic effects in the treatment of depression in women.
    Kornstein SG; McEnany G
    J Clin Psychiatry; 2000; 61 Suppl 11():18-27. PubMed ID: 10926051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of depression: the current state and perspectives of the development of pharmacological studies].
    Ivanetz NN; Tikhonova YG; Kinkulkina MA; Avdeeva TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):108-16. PubMed ID: 25614913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological aspects of neonatal antidepressant withdrawal.
    Ter Horst PG; Jansman FG; van Lingen RA; Smit JP; de Jong-van den Berg LT; Brouwers JR
    Obstet Gynecol Surv; 2008 Apr; 63(4):267-79. PubMed ID: 18348740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants.
    Lee MS
    Drugs Today (Barc); 2007 Aug; 43(8):569-81. PubMed ID: 17925888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To combine or not to combine? A literature review of antidepressant combination therapy.
    Dodd S; Horgan D; Malhi GS; Berk M
    J Affect Disord; 2005 Dec; 89(1-3):1-11. PubMed ID: 16169088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.